Wall Street equity research analysts covering Quanterix Corporation (QTRX) have established consensus twelve-month price targets clustering around the $3.00 per share mark. Forecast models and institutional estimates indicate modest upside potential from its recent trading ranges, though analysts maintain cautious hold or reduced ratings due to ongoing net operating losses, high research expenditures, and developmental volatility within the clinical diagnostics and life sciences tools sector.